Interesting data suggesting the Pfizer/BioNTech works best as a three-dose vaccine. Initial 3-dose antibody titres being so much higher than 2-dose ones makes a stronger case than I had anticipated for administrating boosters outside just the most at-risk demographies.
Interesting data suggesting the Pfizer/BioNTech works best as a three-dose vaccine. Initial 3-dose antibody titres being so much higher than 2-dose ones makes a stronger case than I had anticipated for administrating boosters outside just the most at-risk demographies.
@BallouxFrancois One month follow up is bogus. Get back to us after a year.
@BallouxFrancois The small (yes, I know, log scale) differences between Wildtype and Delta also surprise me, but maybe that's a sample size issue.
@BallouxFrancois Would like to see results of two doses at this interval.
@BallouxFrancois Surely the most at risk demographies still remain the elderly with 'no dose' - should the 'booster' shots not be going there...?
@BallouxFrancois The chance of getting infected (prior immunity) by the 3rd booster is higher than the 1st or the 2nd . Do the maths 🧮. 😃
@BallouxFrancois I wonder if that would still be the case if the first two doses were administered 3 months instead of 3 weeks apart?